Virus-Fighting Company Aimed at Knocking out HIV Raises $60M

A $60 million funding round will help a biotech company start an early-stage clinical trial aimed at chronic HIV infection.

Excision BioTherapeutics, with offices in San Francisco and Philadelphia, said the round was led by GreatPoint Ventures and included existing investor ARTIS Ventures plus new investors Adjuvant Capital, Norwest Venture Partners, Anzu Partners, Cota Capital, WRVI Capital, IndusAge Partners, Loreda Holdings and Olive Tree Capital.

Excision will use the money for its CRISPR genome-editing on EBT-101 against HIV and to support preclinical EBT-103, targeting a type of virus for progressive multifocus leukoencephalopathy, EBT-104 in herpes simplex virus and EBT-107 for hepatitis B.

Read the full article here.